← FDA Drug Approvals (Drugs@FDA)

RIFAXIMIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: MYLAN PHARMACEUTICALS INC · Approved 2026-01-07

Drug application

FDA Application #

ANDA219687

Application type

Abbreviated New Drug Application (Generic)

Brand name

RIFAXIMIN

Generic name

Rifaximin

Active ingredients

RIFAXIMIN

Dosage form

TABLET

Route

—

Marketing status

None (Tentative Approval)

Sponsor

MYLAN PHARMACEUTICALS INC

First approval

2026-01-07

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown